iNtRON Biotechnology, Inc.

Equities

A048530

KR7048530000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 28/05/2024 am IST			5-day change	1st Jan Change
5,990 ^KRW	-0.17%		-6.26%	-31.78%

13/03	INtRON Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/02	Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer	CI

Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.

March 06, 2023 at 12:45 pm IST

From December 2, 2022 to December 31, 2022, the company has repurchased 324,118 shares, representing 0.97% for KRW 2,997.54 million. With this, the company has completed the repurchase of 324,118 shares, representing 0.97% for KRW 2,997.54 million under the buyback announced on December 2, 2022.

Latest news about iNtRON Biotechnology, Inc.

INtRON Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03	CI
Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer	15/02	CI
INtRON Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Basilea Pharmaceutica Signs Evaluation License, Option Deal With Korea's iNtRON	31/23/31	MT
INtRON Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.	03/23/03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.	03/23/03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.	03/23/03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.	03/23/03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.	03/23/03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.	03/23/03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.	03/23/03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on September 20, 2022.	03/23/03	CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on December 2, 2022, has expired with 324,118 shares, representing 0.97% for KRW 2,997.54 million.	03/23/03	CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on December 2, 2022, has expired with	03/23/03	CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on September 20, 2022, has expired with 294,186 shares, representing 0.87% for KRW 2,998.6 million.	03/23/03	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.	06/23/06	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.	06/23/06	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.	06/23/06	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on July 5, 2022.	06/23/06	CI
INtRON Biotechnology, Inc.'s Equity Buyback announced on July 5, 2022, has expired with 274,732 shares, representing 0.81% for KRW 2,997.69 million.	05/23/05	CI
INtRON Biotechnology Identifies Prophage and Jamphage in the Pancreatic Cancer Related Microbiome	30/23/30	CI
INtRON Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
INtRON Biotechnology, Inc. Confirms Cancer-Controlling Effect of Phageria Drug Candidate in the Organoid Model	04/23/04	CI
Tranche Update on iNtRON Biotechnology, Inc.'s Equity Buyback Plan announced on December 2, 2022.	06/23/06	CI

Chart iNtRON Biotechnology, Inc.

Duration

Period

More charts

Company Profile

iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INTRON BIOTECHNOLOGY, INC.	-31.78%	146M
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B
BIONTECH SE	-10.84%	22.71B
ARGENX SE	-1.19%	21.83B
GENMAB A/S	-10.84%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-15.11%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B

Bio Therapeutic Drugs